CAR T‐cell Immunotherapy-the Living Drugs for Lethal Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 3766
Special Issue Editors
Interests: adoptive therapy; hemato-oncology; hematopoietic stem cells and solid organ transplantation; graft versus host disease; genetic editing
Special Issues, Collections and Topics in MDPI journals
Interests: cell therapy; NK cells; immunotherapy with CAR‐T cells; allogeneic hematopoietic stem cell transplantation
Special Issue Information
Dear Colleagues,
Chimeric Antigen Receptor (CAR) expressed in autologous T cells targeting B‐lymphocyte antigen CD19 has been successful scaled to clinical setting for relapsed/refractory B cell acute lymphoblastic leukemia (B‐ALL) and diffuse B cell lymphoma (DBCL). Tisagenlleclucel (Kymriah) and Axicabtagene ciloleucel (Yescarta) have been the first “living drugs” which have received approval by the regulatory agencies and they are already commercialized by the pharmaceutical industry. However, other CAR expressed on different effector cells targeting tumor specific antigens, and other adapted strategies are being faster developed for other malignancies and catastrophic diseases. The field moves so fast with new challenges which need a perfect match and coordination between basic, translational research, physician, academic and industry, leading regulatory policy to facilitate development, but keeping a safety scenario for the patient. In this current perspective, it has revalued the immunotherapy as a hopeful treatment based on specific cell recognition and activation. The aim of this Special Issue is to provide an overview of the CAR cell field biology from the basic and translational development to the manufacturing and clinical impact and future challenges. We hope that the reports presented by basic and clinical researchers who are experts on the field will be a valuable for continous improvement for the community of researchers and physicians investigating on CAR cells in different diseases and with different aims and objectives.
Dr. Antonio Pérez Martínez
Dr. Patrick Schlegel
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chimeric antigen receptor
- biomarker
- hematological malignancies
- solid tumors
- off the shelf CAR-T cells
- CAR-NK cells
- adapted CAR-T
- academic CAR
- non viral gene transduction
- toxicities management
- CAR-T monitoring
- CAR-T relapse
- immune evasion mechanisms
- trucks
